An insight into the mechanisms of action of selected bioactive compounds against epigenetic targets of prostate cancer : implications on histones modifications
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law..
Prostate cancer is a leading cause of morbidity and mortality among men globally. In this study, we employed an in silico approach to predict the possible mechanisms of action of selected novel compounds reported against prostate cancer epigenetic targets and their derivatives, exhausting through ADMET profiling, drug-likeness, and molecular docking analyses. The selected compounds: sulforaphane, silibinin, 3, 3'-diindolylmethane (DIM), and genistein largely conformed to ADMET and drug-likeness rules including Lipinski's. Docking studies revealed strong binding energy of sulforaphane with HDAC6 (- 4.2 kcal/ mol), DIM versus HDAC2 (- 5.2 kcal/mol), genistein versus HDAC6 (- 4.1 kcal/mol), and silibinin against HDAC1 (- 7.0 kcal/mol) coupled with improved binding affinities and biochemical stabilities after derivatization. Findings from this study may provide insight into the potential epigenetic reprogramming mechanisms of these compounds against prostate cancer and could pave the way toward more success in prostate cancer phytotherapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
In silico pharmacology - 11(2023), 1 vom: 30., Seite 10 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Katsayal, Babangida Sanusi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3, 3’-diindolylmethane |
|---|
| Anmerkungen: |
Date Revised 16.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s40203-023-00148-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355771799 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355771799 | ||
| 003 | DE-627 | ||
| 005 | 20240416232229.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40203-023-00148-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM355771799 | ||
| 035 | |a (NLM)37073308 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Katsayal, Babangida Sanusi |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An insight into the mechanisms of action of selected bioactive compounds against epigenetic targets of prostate cancer |b implications on histones modifications |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Prostate cancer is a leading cause of morbidity and mortality among men globally. In this study, we employed an in silico approach to predict the possible mechanisms of action of selected novel compounds reported against prostate cancer epigenetic targets and their derivatives, exhausting through ADMET profiling, drug-likeness, and molecular docking analyses. The selected compounds: sulforaphane, silibinin, 3, 3'-diindolylmethane (DIM), and genistein largely conformed to ADMET and drug-likeness rules including Lipinski's. Docking studies revealed strong binding energy of sulforaphane with HDAC6 (- 4.2 kcal/ mol), DIM versus HDAC2 (- 5.2 kcal/mol), genistein versus HDAC6 (- 4.1 kcal/mol), and silibinin against HDAC1 (- 7.0 kcal/mol) coupled with improved binding affinities and biochemical stabilities after derivatization. Findings from this study may provide insight into the potential epigenetic reprogramming mechanisms of these compounds against prostate cancer and could pave the way toward more success in prostate cancer phytotherapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 3, 3’-diindolylmethane | |
| 650 | 4 | |a Bioactive compounds | |
| 650 | 4 | |a Epigenetics | |
| 650 | 4 | |a Genistein | |
| 650 | 4 | |a Prostate cancer | |
| 650 | 4 | |a Silibinin | |
| 650 | 4 | |a Sulforaphane | |
| 700 | 1 | |a Forcados, Gilead Ebiegberi |e verfasserin |4 aut | |
| 700 | 1 | |a Yusuf, Abdurrahman Pharmacy |e verfasserin |4 aut | |
| 700 | 1 | |a Lawal, Yunus Aisha |e verfasserin |4 aut | |
| 700 | 1 | |a Jibril, Shehu Aisha |e verfasserin |4 aut | |
| 700 | 1 | |a Nuraddeen, Hussaini |e verfasserin |4 aut | |
| 700 | 1 | |a Ibrahim, Musa Mubarak |e verfasserin |4 aut | |
| 700 | 1 | |a Sadiq, Idris Zubairu |e verfasserin |4 aut | |
| 700 | 1 | |a Abubakar, Murtala Bello |e verfasserin |4 aut | |
| 700 | 1 | |a Malami, Ibrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Abubakar, Ibrahim Babangida |e verfasserin |4 aut | |
| 700 | 1 | |a Muhammad, Aliyu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t In silico pharmacology |d 2013 |g 11(2023), 1 vom: 30., Seite 10 |w (DE-627)NLM236675575 |x 2193-9616 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:1 |g day:30 |g pages:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40203-023-00148-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 1 |b 30 |h 10 | ||